Identifying Mediators of Intervention Effects Within a Randomized Controlled Trial to Motivate Cancer Genetic Risk Assessment Among Breast and Ovarian Cancer Survivors

Jinghua An & Anita Y. Kinney

Abstract

Background

A theory-guided Tailored Counseling and Navigation (TCN) intervention successfully increased cancer genetic risk assessment (CGRA) uptake among cancer survivors at increased risk of hereditary breast and ovarian cancer (HBOC). Understanding the pathways by which interventions motivate behavior change is important for identifying the intervention’s active components.

Purpose

We examined whether the TCN intervention exerted effects on CGRA uptake through hypothesized theoretical mediators.

Methods

Cancer survivors at elevated risk for HBOC were recruited from three statewide cancer registries and were randomly assigned to three arms: TCN (n = 212), Targeted Print (TP, n = 216), and Usual Care (UC, n = 213). Theoretical mediators from the Extended Parallel Process Model, Health Action Planning Approach, and Ottawa Decision Support Framework were assessed at baseline and 1-month follow-up; CGRA uptake was assessed at 6 months. Generalized structural equation modeling was used for mediation analysis.

Results

The TCN effects were most strongly mediated by behavioral intention alone (β = 0.49 and 0.31) and by serial mediation through self-efficacy and intention (β = 0.041 and 0.10) when compared with UC and TP, respectively. In addition, compared with UC, the TCN also increased CGRA through increased perceived susceptibility, knowledge of HBOC, and response efficacy.

Conclusions

Risk communication and behavioral change interventions for hereditary cancer should stress a person’s increased genetic risk and the potential benefits of genetic counseling and testing, as well as bolster efficacy beliefs by helping remove barriers to CGRA. System-level and policy interventions are needed to further expand access.

Funding

NCI NIH HHS

3P30CA072720

NCI NIH HHS

P30 CA118100

NCI NIH HHS

P30 CA072720

ORFDO NIH HHS

75N99021D00009

NCI NIH HHS

R01 CA211625

NCI NIH HHS

HHSN261201800014I

CDC HHS

5NU58DP006279

CLC NIH HHS

75N90021D00009

NHLBI NIH HHS

75N92021D00009

NIEHS NIH HHS

75N96021D00009

National Institutes of Health

R01CA211625

National Cancer Institute

3P30CA072720

National Cancer Institute

P30CA118100

National Cancer Institute

75N91021D00009

Centers for Disease Control and Prevention

5NU58DP006279

Rutgers Cancer Institute of New Jersey

New Mexico Tumor Registry

HHSN261201800014I

New Mexico Tumor Registry

HHSN26100001